| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...628727G |
| P356 | DOI | 10.1371/JOURNAL.PONE.0028727 |
| P932 | PMC publication ID | 3235165 |
| P698 | PubMed publication ID | 22174879 |
| P5875 | ResearchGate publication ID | 51884837 |
| P50 | author | Adi Gilboa-Geffen | Q56754536 |
| Geula Hanin | Q38590342 | ||
| P2093 | author name string | Hermona Soreq | |
| Naomi Melamed-Book | |||
| Maureen Rischmueller | |||
| Susan Lester | |||
| David S Greenberg | |||
| Yochai Wolf | |||
| Estelle R Bennett | |||
| Marjorie Pick | |||
| P2860 | cites work | Acetylcholinesterase--new roles for an old actor | Q24291075 |
| Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation | Q24338135 | ||
| Reflex control of immunity | Q28245909 | ||
| MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase | Q28267386 | ||
| Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjögren's syndrome | Q28344891 | ||
| IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9 | Q28507728 | ||
| The two NF-kappaB activation pathways and their role in innate and adaptive immunity | Q29614355 | ||
| Regulation and function of NF-kappaB transcription factors in the immune system | Q29616427 | ||
| Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality | Q33959166 | ||
| TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. | Q34180844 | ||
| IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation | Q34674495 | ||
| Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers | Q35548532 | ||
| The lymphocytic cholinergic system and its contribution to the regulation of immune activity | Q35599803 | ||
| Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology | Q35815962 | ||
| Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? | Q36068780 | ||
| The NOD mouse: a model of immune dysregulation | Q36072434 | ||
| Primary Sjögren's syndrome: current and emergent aetiopathogenic concepts | Q36163155 | ||
| Therapeutic potential of Toll-like receptor 9 activation | Q36501229 | ||
| RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. | Q51629436 | ||
| Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. | Q53290834 | ||
| Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. | Q53852106 | ||
| Sjögren's syndrome | Q55921808 | ||
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| The thymic theme of acetylcholinesterase splice variants in myasthenia gravis | Q57251017 | ||
| IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation | Q59054264 | ||
| Tryptophan catabolism generates autoimmune-preventive regulatory T cells | Q60494045 | ||
| Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome | Q74024000 | ||
| Essential role of IkappaB kinase alpha in thymic organogenesis required for the establishment of self-tolerance | Q82878815 | ||
| Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells | Q83008486 | ||
| Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? | Q83820549 | ||
| Regulatory T-cell physiology and application to treat autoimmunity | Q36563537 | ||
| Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system | Q36577483 | ||
| The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development | Q36592804 | ||
| Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance | Q36695984 | ||
| Usefulness of mouse models to study the pathogenesis of Sjögren's syndrome | Q36852657 | ||
| TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders | Q37066753 | ||
| Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. | Q37222231 | ||
| Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study | Q37681855 | ||
| Autoimmune response and target autoantigens in Sjogren's syndrome. | Q37772540 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Ligand-induced conformational changes allosterically activate Toll-like receptor 9. | Q38300769 | ||
| Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients | Q38512916 | ||
| NF kappa B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation | Q40395246 | ||
| The innervation of salivary glands as revealed by morphological methods | Q40770892 | ||
| Immune Interferon in the Circulation of Patients with Autoimmune Disease | Q41643954 | ||
| Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. | Q41913046 | ||
| Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands. | Q42444928 | ||
| IDO mediates TLR9-driven protection from experimental autoimmune diabetes. | Q43258639 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e28727 | |
| P577 | publication date | 2011-12-09 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome | |
| P478 | volume | 6 |
| Q51544073 | Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. |
| Q34885269 | Antibody- and aptamer-strategies for GvHD prevention |
| Q89738918 | CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression |
| Q38810021 | Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease. |
| Q87004045 | Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20 |
| Q55154729 | Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease. |
| Q37691215 | Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome. |
| Q38298811 | Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. |
| Q41851949 | Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice |
| Q38945150 | Recent Advances in Aptamers Targeting Immune System |
| Q38840238 | Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models |
| Q59381525 | Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome |
| Q26773176 | Role of α7 nicotinic receptor in the immune system and intracellular signaling pathways |
| Q30469329 | Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions. |
| Q26825196 | The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man |
Search more.